Last reviewed · How we verify

intravenous NAC

Ochsner Health System · FDA-approved active Small molecule Quality 2/100

intravenous NAC is a Small molecule drug developed by Ochsner Health System. It is currently FDA-approved.

At a glance

Generic nameintravenous NAC
SponsorOchsner Health System
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intravenous NAC

What is intravenous NAC?

intravenous NAC is a Small molecule drug developed by Ochsner Health System.

Who makes intravenous NAC?

intravenous NAC is developed and marketed by Ochsner Health System (see full Ochsner Health System pipeline at /company/ochsner-health-system).

What development phase is intravenous NAC in?

intravenous NAC is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing